Development and evaluation of buccal films impregnated with selegiline-loaded nanospheres

References

• Aldhubiab BE. (2013). Formulation and in vitro evaluation of gelatin nanospheres for the oral delivery of selegiline. Curr Nanosci 9:21–5
   Web of Science ®Google Scholar
• Anroop B, Ghosh B, Parcha V, Khanam J. (2009). Transdermal delivery of atenolol: effect of prodrugs and iontophoresis. Curr Drug Deliv 6:280–90
   PubMedGoogle Scholar
• Baijens LW, Speyer R. (2009). Effects of therapy for dysphagia in Parkinson's disease: systematic review. Dysphagia 24:91–102
   PubMed Web of Science ®Google Scholar
• Brichta L, Greengard P, Flajolet M. (2013). Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems. Trends Neurosci 36:543–54
   PubMed Web of Science ®Google Scholar
• Castán H, Ruiz MA, Clares B, Morales ME. (2014). Design, development and characterization of buccal bioadhesive films of Doxepin for treatment of odontalgia. Drug Deliv [Epub ahead of print 27 March 2014]
   PubMed Web of Science ®Google Scholar
• Chen JJ. (2010). Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment. Am J Manag Care 16(Suppl. Implications):S87–93
   PubMed Web of Science ®Google Scholar
• Chen CC, Fang CL, Al-Suwayeh SA, et al. (2011). Transdermal delivery of selegiline from alginate-Pluronic composite thermogels. Int J Pharm 415:119–28
   PubMed Web of Science ®Google Scholar
• Clarke A, Brewer F, Johnson ES, et al. (2003). A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 110:1241–55
   PubMed Web of Science ®Google Scholar
• Connolly BS, Lang AE. (2014). Pharmacological treatment of Parkinson disease: a review. JAMA 311:1670–83
   PubMed Web of Science ®Google Scholar
• Dalpiaz A, Contado C, Mari L, et al. (2014). Development and characterization of PLGA nanoparticles as delivery systems of a prodrug of zidovudine obtained by its conjugation with ursodeoxycholic acid. Drug Deliv 21:221–32
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Constantinescu R, Thompson JP, et al. (2007). Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68:384–6
   PubMed Web of Science ®Google Scholar
• El-Mahrouk GM, El-Gazayerly ON, Aboelwafa AA, Taha MS. (2014). Chitosan lactate wafer as a platform for the buccal delivery of tizanidine HCl: in vitro and in vivo performance. Int J Pharm 467:100–12
   PubMed Web of Science ®Google Scholar
• Fang JY, Hung CF, Chi CH, Chen CC. (2009). Transdermal permeation of selegiline from hydrogel-membrane drug delivery systems. Int J Pharm 380:33–9
   PubMed Web of Science ®Google Scholar
• Feiger AD, Rickels K, Rynn MA, et al. (2006). Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry 67:1354–61
   PubMed Web of Science ®Google Scholar
• Frampton JE, Plosker GL. (2007). Selegiline transdermal system in the treatment of major depressive disorder. Drugs 67:257–65
   PubMed Web of Science ®Google Scholar
• Giovino C, Ayensu I, Tetteh J, Boateng JS. (2012). Development and characterisation of chitosan films impregnated with insulin loaded PEG-b-PLA nanoparticles (NPs): a potential approach for buccal delivery of macromolecules. Int J Pharm 428:143–51
   PubMed Web of Science ®Google Scholar
• Jaipal A, Pandey MM, Charde SY, et al. (2014). Controlled release effervescent buccal discs of buspirone hydrochloride: in vitro and in vivo evaluation studies. Drug Deliv 1–7 [Epub ahead of print 3 June 2014]
   PubMed Web of Science ®Google Scholar
• Jay S, Fountain W, Cui Z, Mumper RJ. (2002). Transmucosal delivery of testosterone in rabbits using novel bi-layer mucoadhesive wax-film composite disks. J Pharm Sci 91:2016–25
   PubMed Web of Science ®Google Scholar
• Jenner P, McCreary AC, Scheller DK. (2011). Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression. J Neural Transm 118:1691–702
   PubMed Web of Science ®Google Scholar
• Kocbek P Obermajer N, Cegnar M, et al. (2007). Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release 120:18–26
   PubMed Web of Science ®Google Scholar
• Kumria R, Nair AB, Al-Dhubiab BE. (2014a). Loratidine buccal films for allergic rhinitis: development and evaluation. Drug Dev Ind Pharm 40:625–31
   PubMed Web of Science ®Google Scholar
• Kumria R, Nair AB, Goomber G, Gupta S. (2014b). Buccal films of prednisolone with enhanced bioavailability. Drug Deliv 1–8 [Epub ahead of print 3 June 2014]
   Web of Science ®Google Scholar
• Lv Q, Shen C, Li X, et al. (2014). Mucoadhesive buccal films containing phospholipid-bile salts-mixed micelles as an effective carrier for Cucurbitacin B delivery. Drug Deliv [Epub ahead of print 27 January 2014]
   PubMed Web of Science ®Google Scholar
• Marjama-Lyons J, Koller W. (2000). Tremor-predominant Parkinson's disease. Approaches to treatment. Drugs Aging 16:273–8
   PubMed Web of Science ®Google Scholar
• Nair A, Gupta R, Vasanti S. (2007). In vitro controlled release of alfuzosin hydrochloride using HPMC-based matrix tablets and its comparison with marketed product. Pharm Dev Technol 12:621–5
   PubMed Web of Science ®Google Scholar
• Nair AB, Kumria R, Harsha S, et al. (2013). In vitro techniques to evaluate buccal films. J Control Release 166:10–21
   PubMed Web of Science ®Google Scholar
• Needham E, Worth P. (2012). Parkinson's disease: a guide to pharmacological management. Prescriber 23:21–31
   Google Scholar
• Nerkar PP, Gattani S. (2011). In vivo, in vitro evaluation of linseed mucilage based buccal mucoadhesive microspheres of venlafaxine. Drug Deliv 18:111–21
   PubMed Web of Science ®Google Scholar
• Nyholm D. (2006). Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update. Clin Pharmacokinet 45:109–36
   PubMed Web of Science ®Google Scholar
• Onofrj M, Bonanni L, Thomas A. (2008). An expert opinion on safinamide in Parkinson's disease. Expert Opin Investig Drugs 17:1115–25
   PubMed Web of Science ®Google Scholar
• Palem CR, Gannu R, Yamsani SK, et al. (2011). Development of bioadhesive buccal tablets for felodipine and pioglitazone in combined dosage form: in vitro, ex vivo, and in vivo characterization. Drug Deliv 18:344–52
   PubMed Web of Science ®Google Scholar
• Perioli L, Ambrogi V, Angelici F, et al. (2004). Development of mucoadhesive patches for buccal administration of ibuprofen. J Control Release 99:73–82
   PubMed Web of Science ®Google Scholar
• Prakash KM, Tan EK. (2010). Development of Parkinson's disease biomarkers. Expert Rev Neurother 10:1811–25
   PubMed Web of Science ®Google Scholar
• Rana P, Murthy RS. (2013). Formulation and evaluation of mucoadhesive buccal films impregnated with carvedilol nanosuspension: a potential approach for delivery of drugs having high first-pass metabolism. Drug Deliv 20:224–35
   PubMed Web of Science ®Google Scholar
• Senek M, Nyholm D. (2014). Continuous drug delivery in Parkinson's disease. CNS Drugs 8:19–27
   Web of Science ®Google Scholar
• Sudhakar Y, Kuotsu K, Bandyopadhyay AK. (2006). Buccal bioadhesive drug delivery-a promising option for orally less efficient drugs. J Control Release 114:15–40
   PubMed Web of Science ®Google Scholar
• Tetrud JW, Koller WC. (2004). A novel formulation of selegiline for the treatment of Parkinson's disease. Neurology 63:S2–6
   PubMed Web of Science ®Google Scholar
• Wimbiscus M, Kostenko O, Malone D. (2010). MAO inhibitors: risks, benefits, and lore. Cleve Clin J Med 77:859–82
   PubMed Web of Science ®Google Scholar